Tarsus Pharmaceuticals, Inc.
NASDAQ:TARSBiotechnology
+$0.29 today
- Market cap
- $3.74B
- Beta
- 0.51
- P/E (TTM)
- -55.9
- EPS (TTM)
- -$1.12
Volume 0.45M
Average 0.61M
TARS Net Income
Bottom-line profit after all expenses, interest, and taxes.
Tarsus Pharmaceuticals, Inc.NASDAQ: TARS
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income remains negative
Q3 FY2026 net income was -$668.33M, compared with -$12.59M a year earlier. Trailing-twelve-month net income was -$702.23M.
Context
- Net income amounted to 14.7% of revenue in FY2025, down 48.4 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$640.95M (-865.0%) for the fiscal year ending Dec 2026, a slowdown from the +42.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$668.33M-3502.7% QoQ
- Last fiscal yearDec 2025
- -$66.42M+42.5% YoY
- LTMSep 2026
- -$702.23M-765.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -5210.6% | -56.2% | +5154.4 pp |
| 1 year | +42.5% | -865.0% | -907.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (66.42M) USD
- Year-over-year change
- +42.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (66.42M) | +42.5% |
| FY2024 | 2024-12-31 | (115.55M) | +15.0% |
| FY2023 | 2023-12-31 | (135.89M) | -118.9% |
| FY2022 | 2022-12-31 | (62.09M) | -349.1% |
| FY2021 | 2021-12-31 | (13.83M) | — |
Net Income vs competitors
How TARS compares with its peers on the latest reported figures
- TARS's LTM Sep 2026 net income of -$702.23M is the lowest of the 6 companies compared; the peer median is -$3.84M.
- Its year-over-year change of -765.3% is the lowest of 5, against a peer median of +82.5%.
- Net income amounts to 102.9% of revenue for TARS, versus a peer median of 5.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $28.52M | +130.6% | — | 6.1% | |
| LTM Mar 2026 | -$1.05M | +92.0% | — | 5.7% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | -$3.84M | — | — | — |
| LTM Mar 2026 | -$14.96M | +31.0% | — | 5.6% | |
| LTM Mar 2026 | -$17.83M | +73.0% | — | 48.0% | |
| LTM Sep 2026 | -$702.23M | -765.3% | — | 102.9% | |
| Peer median (excluding TARS) | -$3.84M | +82.5% | — | 5.9% | |
Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 57.03M | 25.82M | 17.45M | 182.95M | 451.36M |
| Cost of Revenue | 2.08M | 955K | 1.59M | 12.83M | 30.68M |
| Gross Profit | 54.95M | 24.86M | 15.85M | 170.13M | 420.68M |
| Gross Margin | 96.4% | 96.3% | 90.9% | 93.0% | 93.2% |
| Research & Development | 41.71M | 42.62M | 50.31M | 53.39M | 64.32M |
| Selling, General & Admin | 25.4M | 44.95M | 108.7M | 237.31M | 427.32M |
| Operating Expenses | 67.11M | 87.57M | 159.01M | 290.7M | 491.65M |
| Depreciation & Amortization | 312K | 326K | 877K | 1.23M | 1.82M |
| EBITDA | (13.46M) | (59.71M) | (131.67M) | (106.48M) | (53.61M) |
| EBITDA Margin | -23.6% | -231.3% | -754.7% | -58.2% | -11.9% |
| Operating Income | (12.16M) | (62.71M) | (143.16M) | (120.57M) | (70.97M) |
| Operating Margin | -21.3% | -242.9% | -820.5% | -65.9% | -15.7% |
| Interest Income | 36K | 3.5M | 10.34M | 15.01M | 15.75M |
| Interest Expense | 0 | 2.06M | 3.23M | 7.45M | 8.94M |
| Other Income / Expenses | (1.62M) | 617K | 7.27M | 5.02M | 6.61M |
| Income Before Tax | (13.77M) | (62.1M) | (135.89M) | (115.55M) | (64.36M) |
| Pre-Tax Margin | -24.1% | -240.5% | -778.9% | -63.2% | -14.3% |
| Income Tax Expense | 55K | (4K) | 0 | 0 | 2.06M |
| Net Income | (13.83M) | (62.09M) | (135.89M) | (115.55M) | (66.42M) |
| Net Margin | -24.2% | -240.5% | -778.9% | -63.2% | -14.7% |
| EPS (Basic) | (0.67) | (2.52) | (4.62) | (3.07) | (1.59) |
| EPS (Diluted) | (0.67) | (2.52) | (4.62) | (3.07) | (1.59) |
| Weighted Avg Shares | 20.55M | 24.62M | 29.38M | 37.6M | 41.78M |
| Weighted Avg Shares (Diluted) | 20.55M | 24.62M | 29.38M | 37.6M | 41.78M |
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
Intrinsic Alpha fair value
Locked
Current Price
$75.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.